An innovative antimicrobial technology has been announced that claims to be able to defeat hospital- and community-acquired infections, including those caused by Clostridium difficile and PVL toxin-bearing methicillin-resistant Staphylococcus aureus (MRSA) strains.
Significantly, this approach defeats drug- resistant bacteria, preventing them from mutating into new resistant strains. It introduces major safety and efficacy benefits to medical science and, crucially, sidesteps the issues associated with traditional drugs.
www.imperial.ac.uk